Next Article in Journal
Oxygenated Polyketides from Plakinastrella mamillaris as a New Chemotype of PXR Agonists
Next Article in Special Issue
pH-Dependent Solution Structure and Activity of a Reduced Form of the Host-Defense Peptide Myticin C (Myt C) from the Mussel Mytilus galloprovincialis
Previous Article in Journal
Nepheliosyne B, a New Polyacetylenic Acid from the New Caledonian Marine Sponge Niphates sp.
Previous Article in Special Issue
Conopeptides from Cape Verde Conus crotchii
Article Menu

Export Article

Open AccessReview
Mar. Drugs 2013, 11(7), 2293-2313;

Strategies for the Development of Conotoxins as New Therapeutic Leads

Monash Institute of Pharmaceutical Science, Monash University, 381 Royal Parade, Parkville 3052, Australia
Author to whom correspondence should be addressed.
Received: 14 April 2013 / Revised: 27 May 2013 / Accepted: 6 June 2013 / Published: 28 June 2013
(This article belongs to the Special Issue Marine Peptides and Their Mimetics)
Full-Text   |   PDF [659 KB, uploaded 24 February 2015]   |  


Peptide toxins typically bind to their target ion channels or receptors with high potency and selectivity, making them attractive leads for therapeutic development. In some cases the native peptide as it is found in the venom from which it originates can be used directly, but in many instances it is desirable to truncate and/or stabilize the peptide to improve its therapeutic properties. A complementary strategy is to display the key residues that make up the pharmacophore of the peptide toxin on a non-peptidic scaffold, thereby creating a peptidomimetic. This review exemplifies these approaches with peptide toxins from marine organisms, with a particular focus on conotoxins. View Full-Text
Keywords: peptide toxin; peptidomimetic; ion channel; pain; cone snail peptide toxin; peptidomimetic; ion channel; pain; cone snail

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Brady, R.M.; Baell, J.B.; Norton, R.S. Strategies for the Development of Conotoxins as New Therapeutic Leads. Mar. Drugs 2013, 11, 2293-2313.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top